Ivis 50

Manufactured by PerkinElmer

Sourced in United States

The IVIS 50 is a bioluminescence and fluorescence imaging system designed for in vivo and ex vivo studies. It enables non-invasive real-time monitoring of biological processes in small animal models.

Automatically generated - may contain errors

Lab products found in correlation

D luciferin, by GoldBio (7 mentions) Living image software, by PerkinElmer (3 mentions) Living image 4, by PerkinElmer (3 mentions) Ivis lumina, by PerkinElmer (2 mentions) Phosphate buffered saline (pbs), by GoldBio (2 mentions) Ivis spectrum, by PerkinElmer (1 mentions) Ivis 200, by PerkinElmer (1 mentions) Black walled 96 well plates, by Thermo Fisher Scientific (1 mentions) Ivis 100, by PerkinElmer (1 mentions) Eb dye, by Merck Group (1 mentions) Akalumine hcl, by Merck Group (1 mentions) Living image 2, by PerkinElmer (1 mentions) Beetle luciferin, by Promega (1 mentions) D luciferin, by Biosynth (1 mentions) μquant microplate spectrophotometer, by Agilent Technologies (1 mentions) Ivis spectrum ct, by PerkinElmer (1 mentions) D luciferin, by Merck Group (1 mentions)

Close spelling variants of this product

IVIS 50 Imaging System (11 citations) IVIS-50 system (4 citations) Xenogen IVIS-50 Bioluminescence Imaging System (2 citations) In Vivo Imaging System (IVIS 50, (2 citations)

30 protocols using ivis 50

In Vivo Bioluminescence Imaging Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols

In vivo bioluminescence imaging was performed on an IVIS 50 (PerkinElmer; Living Image 4.3.1), with exposures of 1 s to 1 min, binning 2–8, field of view 12.5 cm, f/stop 1, and open filter. D-Luciferin (150 mg/kg in PBS; Gold Biotechnology) was injected into the mice i.p. and imaged ventrally using isoflurane anesthesia (2% vaporized in O₂). The total photon flux (photons/s) was measured from regions of interest using the Living Image 2.6 program.
Cells and mesenteries were imaged using the IVIS 50 with (PerkinElmer; Living Image 4.3.1) 1-s to 1-min exposure, bin 4–8, field of view 12 cm, f/stop 1, and open filter after addition of 150 µg/ml D-Luciferin (Gold Biotechnology). For analysis, a grid was placed over the plate, and total photon flux (photons/s) was measured using Living Image 2.6.

Zhang N., Kim S.H., Gainullina A., Erlich E.C., Onufer E.J., Kim J., Czepielewski R.S., Helmink B.A., Dominguez J.R., Saunders B.T., Ding J., Williams J.W., Jiang J.X., Segal B.H., Zinselmeyer B.H., Randolph G.J, & Kim K.W. (2021). LYVE1+ macrophages of murine peritoneal mesothelium promote omentum-independent ovarian tumor growth. The Journal of Experimental Medicine, 218(12), e20210924.

+ Open protocol

+ Expand

In vivo and ex vivo Bioluminescence Imaging

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

In vivo and ex vivo BLI was performed on IVIS50 (PerkinElmer, Waltham, MA) as previously described (20 (link)). Total photon flux (photons/sec) was measured from fixed regions of interest (ROIs) over entire mouse or manually around ex vivo organs using Living Image 2.6, as indicated. Mice with outstanding chest BLI intensity indicative of a failed intracardiac injection or with ineffective D-luciferin administration were excluded from all analyses. Investigators were blinded to treatment groups during all BLI analyses.

Ross M.H., Esser A.K., Fox G.C., Schmieder A.H., Yang X., Hu G., Pan D., Su X., Xu Y., Novack D.V., Walsh T., Colditz G.A., Lukaszewicz G.H., Cordell E., Novack J., Fitzpatrick J.A., Waning D.L., Mohammad K.S., Guise T.A., Lanza G.M, & Weilbaecher K.N. (2017). Bone-induced expression of integrin β3 enables targeted nanotherapy of breast cancer metastases. Cancer research, 77(22), 6299-6312.

+ Open protocol

+ Expand

Metastatic 4T1-3R Mouse Model

Check if the same lab product or an alternative is used in the 5 most similar protocols

We used 4-week-old females BALB/c mice (N = 4) purchased from the National Laboratory Animal Center of Taiwan after 1 week of housing and quarantine for the establishment of a metastatic animal model. In total, 1 × 10⁶ 4T1-3R cells expressing a firefly luciferase gene were resuspended in 50 μL of OPTI-MEM and injected into the right leg of the mice subcutaneously, using a 27G needle. To monitor tumor growth and metastasis formation, fluorescent signals were detected by an In Vivo Imaging System (IVIS 50, Perkin Elmer Inc., Waltham, MA, USA) twice a week, and tumor sizes were measured by a caliper. The mice were sacrificed after metastatic lesions were confirmed by IVIS 50. Animal experiments were approved by the Institutional Animal Care and Utilization Committee (IACUC) of National Yang-Ming University, IACUC no. 1050422, 28 April 2016.

Wang C.Y., Chang C.Y., Wang C.Y., Liu K., Kang C.Y., Lee Y.J, & Chen W.R. (2019). N-Dihydrogalactochitosan Potentiates the Radiosensitivity of Liver Metastatic Tumor Cells Originated from Murine Breast Tumors. International Journal of Molecular Sciences, 20(22), 5581.

+ Open protocol

+ Expand

Bioluminescence Imaging of D-luciferin in Animals

Check if the same lab product or an alternative is used in the 5 most similar protocols

Animals were given 150 μg/mL D-luciferin (Gold Biotech) in PBS through intraperitoneal injection and imaged with a charge-coupled device (CCD) camera-based bioluminescence imaging system (IVIS50; Perkin-Elmer, Hopkinton, MA) with exposure time 10 secs - 1 minute, binning 8, field of view 12, f/stop 1, open filter. Signal was displayed as photons/sec/cm²/sr [45 (link)].

Chen Y.H., Cimino P.J., Luo J., Dahiya S, & Gutmann D.H. (2016). ABCG1 maintains high-grade glioma survival in vitro and in vivo. Oncotarget, 7(17), 23416-23424.

+ Open protocol

+ Expand

In Vivo and In Vitro Bioluminescence Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols

In vitro or in vivo assays for luciferase expression were performed with IVIS 50, IVIS 200 or IVIS Spectrum systems (Xenogen product line of Perkin-Elmer), which are located in the Stanford Center for Innovation in In-Vivo Imaging (http://med.stanford.edu/mips/aboutus/facilities/sci3.html) or the MSU IQ Imaging Core Facility. For in vitro assays, D-luciferin (300 μg/mL) was added to cultures prior to BLI. For in vivo imaging, mice were anesthetized with isoflurane using a SAS3 anesthesia system (Summit Anesthesia Support) and an EVAC 4 waste gas evacuation system (Universal Vaporizer Support). After intraperitoneal injection of D-luciferin (150 mg/kg) emitted photons were captured as described [14 (link)], and bioluminescent signals were analyzed with Living Image software (Perkin-Elmer).

Kanada M., Kim B.D., Hardy J.W., Ronald J.A., Bachmann M.H., Bernard M.P., Perez G.I., Zarea A.A., Ge T.J., Withrow A., Ibrahim S.A., Toomajian V., Gambhir S.S., Paulmurugan R, & Contag C.H. (2019). Microvesicle-mediated delivery of minicircle DNA results in effective gene-directed enzyme prodrug cancer therapy. Molecular cancer therapeutics, 18(12), 2331-2342.

+ Open protocol

+ Expand

Bioluminescence Imaging of Tumor Progression

Check if the same lab product or an alternative is used in the 5 most similar protocols

Three days after injection of tumor cells, mice were imaged using IVIS. Mice were first anesthetized in an induction chamber using a concentration of 4%-5% isoflurane. Next, a subcutaneous injection of 100 ml of D-Luciferin Substrate (purchased from Caliper LS and diluted in 35 ml of deionized H 2 O with a final concentration of 28.57 mg/ml) was administered. These mice were weighed and then transferred to the imaging chamber, where anesthesia was maintained with a concentration of 1%-2% isoflurane emitted through nose cones. Five minutes postinjection of D-Luciferin, imaging using the IVIS 50 (PerkinElmer) was performed according to the manufacturer's protocol. The IVIS was run for 1 minute and bioluminescence was recorded. The imaging was considered positive for tumor if there was a measureable amount of bioluminescence. If no signal was seen, reimaging was performed by immediately running the IVIS for 1 more minute. If no signal was seen on multiple repeat images, the imaging was considered negative for tumor. Imaging was performed on days 3, 7, 14, 21, 28, 35, and 42 after tumor cell injection. Confirmation of tumor progression is shown by MRI (Fig. 1F) and IVIS (Fig. 1G-K).

Payne R., Mrowczynski O.D., Slagle-Webb B., Bourcier A., Mau C., Aregawi D., Madhankumar A.B., Lee S.Y., Harbaugh K., Connor J, & Rizk E.B. (2019). MLN8237 treatment in an orthoxenograft murine model for malignant peripheral nerve sheath tumors. Journal of neurosurgery, 130(2).

+ Open protocol

+ Expand

Coculture Assay for Fibroblast-Keratinocyte Interaction

Check if the same lab product or an alternative is used in the 5 most similar protocols

Coculture experiments were performed as previously described with the following modifications [7 (link)]. A total of 1.3 × 10⁴ fibroblasts were plated in black-walled 96-well plates (Fisher Scientific). Cells were incubated in starve medium (DMEM + 1% penicillin/streptomycin) for 3 days before the addition of HaCAT-CBR cells. HaCAT-CBR cells were cultured in starve medium for 24 hours before plating on fibroblasts. A total of 1.0 × 10³ HaCAT-CBR cells were plated on fibroblasts and incubated for six days. On day six, live-cell bioluminescence imaging was performed on an IVIS 50 (PerkinElmer; Living Image 4.3, 1 min exposure, bin8, FOV12cm, f/stop1, open filter). D-luciferin (150mg/ml; Gold Biotechnology, St. Louis, MO) was added to black-walled plates 10 min prior to imaging.

Flanagan K.C., Alspach E., Pazolli E., Parajuli S., Ren Q., Arthur L.L., Tapia R, & Stewart S.A. (2017). c-Myb and C/EBPβ regulate OPN and other senescence-associated secretory phenotype factors. Oncotarget, 9(1), 21-36.

+ Open protocol

+ Expand

Bioluminescence Imaging of Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

For BLI of live animals, mice were injected intraperitoneally with 150 μg /g D-luciferin (Gold Biotechnology, St. Louis, MO) in PBS, anesthetized with 2.5% isoflurane, and imaged with a charge-coupled device (CCD) camera-based system (IVIS 50, PerkinElmer, Waltham, MA; Living Image 4.3.1, exposure time 10–60 seconds, binning 8, field of view 12cm, f/stop 1, open filter, ventral view). Luminescence was displayed as photons/sed/cm2/sr. Regions of interest (ROI) were defined manually over the lower abdomen using Living Image 2.6 with measurements reported as photons/sec.

Beversdorf D.Q., Smith B.W., Crucian G.P., Anderson J.M., Keillor J.M., Barrett A.M., Hughes J.D., Felopulos G.J., Bauman M.L., Nadeau S.E, & Heilman K.M. (2000). Increased discrimination of “false memories” in autism spectrum disorder. Proceedings of the National Academy of Sciences of the United States of America, 97(15), 8734-8737.

+ Open protocol

+ Expand

Bioluminescence Imaging for Metastatic Tumor Burden

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

BLI was performed as previously described (42 (link)). In vivo imaging was performed on an IVIS50 or IVIS Lumina (PerkinElmer, Downers Grove, IL; Living Image 3.2, 1–60sec exposures, binning 4, 8 or, 16, FOV 15cm, f/stop1, open filter). Mice were injected intraperitoneally with D-luciferin (150mg/kg in PBS; Gold Biotechnology) and imaged 10 minutes later under isoflurane anesthesia (2% vaporized in O2). For ex vivo imaging, animals were sacrificed immediately following whole body imaging and both hind limbs and organs were isolated and imaged for 10 seconds. For analysis, total photon flux (photons/sec) was measured from a fixed region of interest (ROIs) over the whole body, hindlimbs or bones using Living Image 2.6 software. For all experiments using intracardiac injections, disseminated metastatic tumor burden was assessed on day 12/13/14 after tumor cell implantation as indicated in figure legends, with the exception of the experiment using PyMT-BO1-OVA cell line where metastatic tumor burden was assessed dynamically by weekly BLI. For live imaging, data was plotted as fold-change relative to day 1/2 after tumor cell implantation when available.

Evers M., Saftig P., Schmidt P., Hafner A., McLoghlin D.B., Schmahl W., Hess B., von Figura K, & Peters C. (1996). Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI.. Proceedings of the National Academy of Sciences of the United States of America, 93(16), 8214-8219.

+ Open protocol

+ Expand

Evaluating 188Re-Liposome Tumor Response

Check if the same lab product or an alternative is used in the 5 most similar protocols

CLI was performed at 24 hours after the administration of 188 Re-liposome. The signals were acquired by the in vivo Imaging System (IVIS 50, Perkin Elmer Inc., Waltham, MA, USA). Regions of interest (ROIs) were delineated on the tumor around the mouth. For evaluation of tumor response to 188 Reliposome, resection of tumors with various treatment were performed and compared by size.

Wang S., Liang-Ting L., Lin B., Chang C., Chun-Yuan C., Lin M., & Lee Y. (2021). A comparative study of single or dual treatment of theranostic 188Re-Liposome on microRNA expressive profiles of orthotopic human head and neck tumor model. Heighpubs Otolaryngology and Rhinology, 5(1), 001-012.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!